AACR logo

More articles from Therapeutic Agents: Biological

Abstract C025: HexaBody-DR5/DR5 (GEN1029) shows potent preclinical antitumor activity in a variety of patient-derived xenograft (PDX) tumor models
Marije B Overdijk, Michael Cecchini, Kristin Strumane, Marcel Brandhorst, Andreas Lingnau, Paul W.H.I. Parren, Merete Ellekilde-Pedersen, Ulf Forssmann, Tahamtan Ahmadi, A. Kate Sasser, Janine Schuurman, Esther C.W. Breij, Patricia LoRusso

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C025; DOI: 10.1158/1535-7163.TARG-19-C025
Abstract C024: Ribitol enhances O-mannosylation of α-DG in breast cancer cells
qi L Lu, Pei J Lu, Jason D Tucker, Elizabeth K Branch, Fei Guo, Anthony R Blaeser

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C024; DOI: 10.1158/1535-7163.TARG-19-C024
Abstract C030: A new low potency DNA guanine monoalkylating ADC payload with enhanced in vivo tolerability
Nicolas Veillard, Paolo Andriollo, Francesco Cascio, Paul J. M. Jackson, David E. Thurston

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C030; DOI: 10.1158/1535-7163.TARG-19-C030
Abstract C023: IKS01, a next generation antibody drug conjugate, shows target-dependent efficacy in a platinum-resistant tumor model with low levels of folate receptor α expression
Jenny Thirlway, Adam Lodge, Andria Pelava, Daniel J Williamson, Davide Carta, Majid Al Nakeeb, Justyna Mysliwy, Paul J.M. Jackson, David E Thurston, Robert J Lutz

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C023; DOI: 10.1158/1535-7163.TARG-19-C023
Abstract C028: Discovery and characterization of next generation monoclonal antibodies targeting the inhibitory Fc gamma receptor CD32b for the treatment of B and plasma cell malignancies
Haihui Lu, Dongshu Chen, Sunyoung Jang, Babette Wolf, Stefan Ewert, Meghan Flaherty, Fangmin Xu, Sinan Isim, Yeonjiu Shim, Christina Dornelas, Nicole Balke, Xavier Charles Leber, Meike Scharenberg, Johanna Koelln, Eugene Choi, Rebecca Ward, Jennifer Johnson, Thomas Calzascia, Isabelle Isnardi, Juliet Williams, Heather Huet, Emma Lees, Matthew J Meyer

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C028; DOI: 10.1158/1535-7163.TARG-19-C028
Abstract B120: TAK-164, a GCC-targeted antibody-drug conjugate (ADC) for the treatment of colorectal cancers and other GI malignancies
Adnan O. Abu-Yousif, Bret M. Bannerman, Donna Cvet, Melissa Gallery, Michelle L. Ganno, Michael D. Smith, Katharine C. Lai, Thomas A. Keating, Jayaprakasam Bolleddula, Bradley Stringer, Mark G. Qian, Afrand Kamali, Kurt Eng, Secil Koseoglu, Cindy Q. Xia, O. Petter Veiby

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B120; DOI: 10.1158/1535-7163.TARG-17-B120
Abstract B105: ACTR707: a novel T-cell therapy for the treatment of relapsed or refractory CD20+ B cell lymphoma in combination with rituximab
Greg Motz, Kathleen Whiteman, John Shin, Tapasya Pai, Casey Judge, Anthony Barnitz, James Hemphill, James Kim, Ann Ranger, Heather Huet, Kathleen McGinness, Birgit Schultes, Geoffrey Hodge, Michael Vasconcelles, Seth Ettenberg

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B105; DOI: 10.1158/1535-7163.TARG-17-B105
Abstract LB-B25: Preliminary phase I data comparing HuMab-5B1 (MVT-5873), a monoclonal antibody targeting sLea, as a single agent and in combination with first line nab-paclitaxel and gemcitabine in patients with CA19-9 positive pancreatic cancer
Eileen Mary O'Reilly, Judy Sing-Zan Wang, Kenneth H. Yu, Maeve Aine Lowery, Anna M. Varghese, Johanna C. Bendell, Erkut Hasan Borazanci, Hayley Estrella, Kimberly Fowler, Mariella Hoskins, Stephanie Bussen, Teresa J. Melink, Christine M. Kearns, H Toni Jun, Paul W. Maffuid, John C. Gutheil, Todd Michael Bauer

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) LB-B25; DOI: 10.1158/1535-7163.TARG-17-LB-B25
Abstract B113: Development of a novel synthetic consensus DNA vaccine that targets multiple MAGE-A family members for anticancer immune therapy
Elizabeth K. Duperret, Aspen Trautz, Megan Paik, Charles Reed, Jian Yan, David B. Weiner

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B113; DOI: 10.1158/1535-7163.TARG-17-B113
Abstract B121: The benefits of bispecific mAb² antibodies targeting EGFR and HGF
Kin-Mei Leung

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B121; DOI: 10.1158/1535-7163.TARG-17-B121

Main menu

User menu

Search

More articles from Therapeutic Agents: Biological

Pages

Articles

Info for

About MCT